Cinnamomum burmannii, Lagerstroemia speciosa
HerbaWELL Diabetadex
HerbaWELL Diabetadex is an herbal product that contains DLBS3233, a standardized extract made from a combination of Lagerstroemia speciosa and Cinnamomum burmannii. These plants are well-known for their antidiabetic properties. DLBS3233 has been studied in vitro, in vivo, and clinical studies, demonstrating its effectiveness as a treatment for people with type 2 Diabetes and possibly also for diabetes prevention.
HerbaWELL Diabetadex is available in capsule form, with two available doses of 50 mg and 100 mg.
A Brief Introduction to Our Product
DLBS3233 has a mechanism of action that focuses on key molecular pathways to enhance insulin signaling and sensitivity. This mechanism involves upregulating important proteins, including PPARγ, PPARδ, PI3 kinase, Akt, GLUT4, and adiponectin, while down-regulating resistin. This further improves insulin sensitivity and facilitates more effective glucose uptake in peripheral tissues. Thus, it highlights the role of DLBS3233 in managing blood glucose levels in individuals with type 2 diabetes.
Product Functions
The mode of action of DLBS3233 is complex and involves the integration of various mechanisms. In vitro studies conducted by DLBS indicate that DLBS3233 enhances glucose uptake capacity and increases the expression of genes associated with improved insulin signaling and sensitivity. These genes include PPARγ, PPARδ, PI3 kinase, Akt, and GLUT4. Additionally, treatment with DLBS3233 leads to increased adiponectin secretion, an adipocyte-specific protein that enhances insulin sensitivity through increased fatty acid oxidation and the inhibition of hepatic glucose production. Moreover, DLBS3233 reduces the secretion of resistin, a protein secreted by adipose tissue involved in developing insulin resistance. All those parameters were studied compared to Pioglitazone, in which DLBS3233 showed a similar result to Pioglitazone.
Additionally, our research on insulin-resistant rats showed that DLBS3233 effectively regulates blood glucose, insulin, and cholesterol levels. Treatment with DLBS3233 also resulted in a notable decrease in the HOMA index.
Furthermore, DLBS3233 has proven to be an effective treatment combination: clinical trials involving type-2 diabetic patients revealed that when it is combined with other oral antidiabetic agents, it significantly decreases HbA1c levels after six weeks of treatment. A reduction in insulin resistance, as measured by HOMA-IR, was also observed after this period. In line with the improvements in glycemic control and insulin resistance, a notable increase in adiponectin levels was recorded after twelve weeks of treatment with DLBS3233.
Another important advantage of DLBS3233 is its effectiveness in prediabetic patients, as demonstrated by clinical trials. These trials showed a reduction in HOMA-IR and an improvement in beta cell performance, suggesting DLBS3233's potential to prevent the progression of diabetes.
Importantly, DLBS3233 has been associated with a low risk of causing hypoglycemia, as confirmed in a clinical trial involving non-obese, healthy subjects with normal glucose levels.
Insights and Discoveries
Dosage Instructions
HerbaWELL Diabetadex 50 mg capsules: 2 capsules daily.
HerbaWELL Diabetadex 100 mg capsules: 1 capsule daily.
If You Miss a Dose
Take it as soon as you remember. If it's almost time for your next dose, skip the missed one. Do not take extra capsules.
Contraindications
Do not take Inlacin if you are allergic to any of its components.
Side Effects
No side effects were noted in studies. HerbaWELL Diabetadex is safe at the recommended dosage. If you experience any unusual symptoms, contact your doctor.
Important Information for Your Doctor/Pharmacist
Please inform them about the following:
Other medications or supplements you’re taking.
Any allergies you have.
If you are pregnant or planning to become pregnant.
Recommendations for Safe Administration and Use of Our Product
This product is protected by five patents that are distributed across Asia, Australia, Europe, and North America.
Our Patent Rights
Store at a temperature below 30°C, in a dry place, and protect from direct sunlight.
Kept out of reach of children.
Storage Conditions
Not yet available overseas.
[HerbaWELL Diabetadex can be found in global markets soon!]
Explore Our Global Markets
DLBS3233 increases Glucose Uptake by mediating upregulation of PPARγ and GLUT4 expression (2011)
Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression (2011)
DLBS3233 extract, a novel insulin sensitizer with negligible risk of hypoglycemia: A phase-I study (2012)
Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa (2016)
Clinical experience with DLBS3233, a combination of cinnamomum burmanii and Lagerstroemia speciosa, for polycictic ovary syndrome treatment (2016)
Molecular analysis of gene expression related to the effects of DLBS3233 treatment in differentiation of 3T3-L1 pre-adipocyte (2016)
DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents (2016)
The effect and safety assessment of metformin and DLBS3233 (a bioactive fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on improving metabolic parameters in women with polycystic ovary syndrome (2023)
Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study (2023)
The efficacy and safety of DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa compared to metformin on endocrine-metabolic profile of women with polycystic ovary syndrome: A randomized clinical trial (2023)